Physician

Gaurav Kumar Verma, M.D.

According to 2025 Medicare claims, Gaurav Verma, M.D. (NPI: 1730201096) practices internal medicine in the Terre Haute, IN market, with the plurality of this provider's patient population coming from Vigo, IN. This provider's primary affiliated billing organization is KIDNEY AND HYPERTENSION CENTER OF WABASH VALLEY, LLC (NPI: 1396182788; TIN: 46-1310272) and primary practice location at 47804-2706. Verma is affiliated with the Ascension Care Management (ACO ID: A2600), IRCCO (ACO ID: A2619), Central Florida ACO (ACO ID: A2801), and Collaborative ACO 30, LLC (ACO ID: A5483), participating under the MSSP model.

Verma's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,371 traditional Medicare patients, billed 7,708 HCPCS/CPT codes, and received $510,090 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 9,278 prescription claims across 1,145 beneficiaries totaling $2,591,322 in drug costs, led by Tolvaptan (Tolvaptan). 2023 DME data shows 64 claims. Open Payments data shows 113 records totaling $60,050. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have risen steadily, from $918,047 to $2,591,322. In contrast, DME billing represents a smaller volume and fell sharply in recent years, from $6,378 to $2,227.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,256	8,809	$667,648
2016	1,598	8,659	$644,317
2017	1,644	6,362	$471,030
2018	1,609	5,351	$375,022
2019	1,823	7,040	$523,382
2020	1,818	9,167	$690,613
2021	1,591	8,352	$710,135
2022	1,509	8,200	$649,173
2023	1,406	7,070	$554,820
2024	1,371	7,708	$510,090

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	592	5,659	$918,047
2016	873	12,378	$1,519,989
2017	950	10,244	$1,484,985
2018	893	9,233	$1,422,003
2019	897	8,511	$1,598,684
2020	893	8,099	$1,203,648
2021	961	8,355	$1,287,318
2022	1,000	9,310	$1,913,995
2023	1,046	8,997	$2,391,861
2024	1,145	9,278	$2,591,322

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	51	$4,311
2016	N/R	67	$2,404
2017	N/R	54	$1,562
2018	70	485	$135,473
2019	54	585	$154,959
2020	27	314	$126,529
2021	13	172	$80,920
2022	N/R	165	$42,223
2023	N/R	64	$13,612
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	395	485	$130
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	425	864	$61
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	484	1,360	$60
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	575	1,009	$57
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	694	1,366	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Tolvaptan	Tolvaptan	85	2,740	$516,655
Farxiga	Dapagliflozin Propanediol	538	23,509	$436,296
Kerendia	Finerenone	266	10,738	$232,901
Velphoro	Sucroferric Oxyhydroxide	49	1,675	$154,727
Filspari	Sparsentan	12	360	$136,610

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	110	$37,862	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	3	$22,189	Bayer Healthcare Pharmaceuticals Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Gaurav Kumar Verma, M.D.?

Tedicare shows public-source Medicare data for Gaurav Kumar Verma, M.D. (NPI 1730201096), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Gaurav Kumar Verma, M.D. have ACO affiliation data?

Gaurav Kumar Verma, M.D. is shown with ACO affiliation data for Ascension Care Management (MSSP, ACO ID A2600), IRCCO (MSSP, ACO ID A2619), Central Florida ACO (MSSP, ACO ID A2801), and Collaborative ACO 30, LLC (MSSP, ACO ID A5483).

What billing organization is linked to Gaurav Kumar Verma, M.D.?

Gaurav Kumar Verma, M.D. is linked to KIDNEY AND HYPERTENSION CENTER OF WABASH VALLEY, LLC (billing NPI 1396182788) in the available physician profile data.

Does Gaurav Kumar Verma, M.D. have Open Payments data?

Gaurav Kumar Verma, M.D. has 113 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.